News
The FDA has removed the recommended pause in the use of Valneva’s chikungunya vaccine Ixchiq in individuals aged 60 years and older.
8h
Medpage Today on MSNSoap Recall Over Sepsis Risk; FDA Rehires Vinay Prasad; NIH Reports Patient to ICENote that some links may require registration or subscription. DermaRite Industries is recalling certain lots of its over-the ...
IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...
British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...
Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...
The uncertainty surrounds who will be able to get updated vaccines in coming months – shots created to protect against more ...
In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...
This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results